Literature DB >> 22351077

Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injury.

Yiru Guo1, Santosh K Sanganalmath, Wenjian Wu, Xiaoping Zhu, Yiming Huang, Wei Tan, Suzanne T Ildstad, Qianhong Li, Roberto Bolli.   

Abstract

Although the late phase of ischemic preconditioning is known to be mediated by increased inducible nitric oxide synthase (iNOS) activity, controversy persists regarding the role of iNOS in ischemia/reperfusion (I/R) injury and, specifically, whether this protein is protective or detrimental. We hypothesized that iNOS is protective in myocytes but detrimental in inflammatory cells. To test this hypothesis, we created chimeric mice with iNOS-deficient peripheral blood cells by transplanting iNOS knockout (KO) bone marrow in wild-type (WT) mice after lethal irradiation. 2 months later, the mice underwent a 30-min coronary occlusion followed by 24 h of reperfusion. In WT naïve mice (iNOS(+/+) naïve; group I, n = 17), infarct size was 56.9 ± 2.8% of the risk region. In iNOS KO naïve mice with whole-body iNOS deletion (iNOS(-/-) naïve; group II, n = 10), infarct size was comparable to group I (53.4 ± 3.5%). When irradiated WT mice received marrow from WT mice (iNOS(+/+) chimera; group III, n = 10), infarct size was slightly reduced versus group I (44.3 ± 3.2%), indicating that irradiation and/or transplantation slightly decrease I/R injury. However, when WT mice received marrow from iNOS KO mice (iNOS(-/-) chimera; group IV, n = 14), infarct size was profoundly reduced (22.8 ± 2.1%, P < 0.05 vs. group III), indicating that selective deletion of iNOS from peripheral blood cells (with no change in myocardial iNOS content) induces protection against myocardial infarction. Together with our previous work showing the cardioprotective actions of NO donors, iNOS gene therapy, and cardiac-specific overexpression of iNOS, these data support a complex, dual role of iNOS in myocardial infarction (i.e., protective in myocytes but deleterious in blood cells). To our knowledge, this is the first study to identify a critical role of iNOS in peripheral blood cells as a mediator of myocardial I/R injury. The results support heretofore unknown differential actions of iNOS depending on cell source and have important translational implications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22351077      PMCID: PMC3640449          DOI: 10.1007/s00395-012-0253-9

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  56 in total

1.  Microdialysis-based analysis of interstitial NO in situ: NO synthase-independent NO formation during myocardial ischemia.

Authors:  Claus Martin; Rainer Schulz; Heiner Post; Kerstin Boengler; Malte Kelm; Petra Kleinbongard; Petra Gres; Andreas Skyschally; Ina Konietzka; Gerd Heusch
Journal:  Cardiovasc Res       Date:  2007-01-03       Impact factor: 10.787

2.  Cardioprotection: nitric oxide, protein kinases, and mitochondria.

Authors:  Gerd Heusch; Kerstin Boengler; Rainer Schulz
Journal:  Circulation       Date:  2008-11-04       Impact factor: 29.690

3.  Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences.

Authors:  Qianhong Li; Yiru Guo; Wei Tan; Adam B Stein; Buddhadeb Dawn; Wen-Jian Wu; Xiaoping Zhu; Xiaoqin Lu; Xiaoming Xu; Tariq Siddiqui; Sumit Tiwari; Roberto Bolli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-09-19       Impact factor: 4.733

4.  Cardioselective nitric oxide synthase 3 gene transfer protects against myocardial reperfusion injury.

Authors:  Zsolt Szelid; Peter Pokreisz; Xiaoshun Liu; Pieter Vermeersch; Glenn Marsboom; Hilde Gillijns; Marijke Pellens; Erik Verbeken; Frans Van de Werf; Desire Collen; Stefan P Janssens
Journal:  Basic Res Cardiol       Date:  2009-12-18       Impact factor: 17.165

5.  Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences.

Authors:  Qianhong Li; Yiru Guo; Wen-Jian Wu; Qinghui Ou; Xiaoping Zhu; Wei Tan; Fangping Yuan; Ning Chen; Buddhadeb Dawn; Li Luo; Erin O'Brien; Roberto Bolli
Journal:  Basic Res Cardiol       Date:  2011-07-21       Impact factor: 17.165

6.  Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via a nuclear factor-{kappa}B-dependent pathway.

Authors:  Qianhong Li; Yiru Guo; Qinghui Ou; Chuanjue Cui; Wen-Jian Wu; Wei Tan; Xiaoping Zhu; Lilibeth B Lanceta; Santosh K Sanganalmath; Buddhadeb Dawn; Ken Shinmura; Gregg D Rokosh; Shuyan Wang; Roberto Bolli
Journal:  Circulation       Date:  2009-09-14       Impact factor: 29.690

7.  Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway.

Authors:  Qianhong Li; Yiru Guo; Wei Tan; Qinghui Ou; Wen-Jian Wu; Diana Sturza; Buddhadeb Dawn; Greg Hunt; Chuanjue Cui; Roberto Bolli
Journal:  Circulation       Date:  2007-09-04       Impact factor: 29.690

8.  Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition.

Authors:  Matthew B West; Gregg Rokosh; Detlef Obal; Murugesan Velayutham; Yu-Ting Xuan; Bradford G Hill; Rachel J Keith; Jürgen Schrader; Yiru Guo; Daniel J Conklin; Sumanth D Prabhu; Jay L Zweier; Roberto Bolli; Aruni Bhatnagar
Journal:  Circulation       Date:  2008-10-20       Impact factor: 29.690

9.  Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury.

Authors:  Ulrike B Hendgen-Cotta; Marc W Merx; Sruti Shiva; Joel Schmitz; Stefanie Becher; Johann P Klare; Heinz-Jürgen Steinhoff; Axel Goedecke; Jürgen Schrader; Mark T Gladwin; Malte Kelm; Tienush Rassaf
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-16       Impact factor: 11.205

10.  Nitric oxide synthase 2 and pressure-overload-induced left ventricular remodelling in mice.

Authors:  Ryuji Hataishi; Ana Clara Rodrigues; John G Morgan; Fumito Ichinose; Geneviève Derumeaux; Kenneth D Bloch; Michael H Picard; Marielle Scherrer-Crosbie
Journal:  Exp Physiol       Date:  2006-03-09       Impact factor: 2.969

View more
  15 in total

Review 1.  The Delay Phenomenon: A Compilation of Knowledge across Specialties.

Authors:  Kristy Hamilton; Erik M Wolfswinkel; William M Weathers; Amy S Xue; Daniel A Hatef; Shayan Izaddoost; Larry H Hollier
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2014-02-21

2.  The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs.

Authors:  Steven P Jones; Xian-Liang Tang; Yiru Guo; Charles Steenbergen; David J Lefer; Rakesh C Kukreja; Maiying Kong; Qianhong Li; Shashi Bhushan; Xiaoping Zhu; Junjie Du; Yibing Nong; Heather L Stowers; Kazuhisa Kondo; Gregory N Hunt; Traci T Goodchild; Adam Orr; Carlos C Chang; Ramzi Ockaili; Fadi N Salloum; Roberto Bolli
Journal:  Circ Res       Date:  2014-12-11       Impact factor: 17.367

3.  Cyclovirobuxinum D suppresses lipopolysaccharide-induced inflammatory responses in murine macrophages in vitro by blocking JAK-STAT signaling pathway.

Authors:  Dan Guo; Jing-Rong Li; Ying Wang; Lin-Sheng Lei; Chuan-Lin Yu; Na-Na Chen
Journal:  Acta Pharmacol Sin       Date:  2014-04-21       Impact factor: 6.150

4.  Endothelial NOS (NOS3) impairs myocardial function in developing sepsis.

Authors:  Annette M van de Sandt; Rainer Windler; Axel Gödecke; Jan Ohlig; Simone Zander; Michael Reinartz; Jürgen Graf; Ernst E van Faassen; Tienush Rassaf; Jürgen Schrader; Malte Kelm; Marc W Merx
Journal:  Basic Res Cardiol       Date:  2013-02-10       Impact factor: 17.165

5.  Genetic background, gender, age, body temperature, and arterial blood pH have a major impact on myocardial infarct size in the mouse and need to be carefully measured and/or taken into account: results of a comprehensive analysis of determinants of infarct size in 1,074 mice.

Authors:  Yiru Guo; Michael P Flaherty; Wen-Jian Wu; Wei Tan; Xiaoping Zhu; Qianhong Li; Roberto Bolli
Journal:  Basic Res Cardiol       Date:  2012-08-03       Impact factor: 17.165

Review 6.  Redox signalling and cardioprotection: translatability and mechanism.

Authors:  P Pagliaro; C Penna
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

7.  Increasing tetrahydrobiopterin in cardiomyocytes adversely affects cardiac redox state and mitochondrial function independently of changes in NO production.

Authors:  Savitha Sethumadhavan; Jennifer Whitsett; Brian Bennett; Irina A Ionova; Galen M Pieper; Jeannette Vasquez-Vivar
Journal:  Free Radic Biol Med       Date:  2016-01-27       Impact factor: 7.376

8.  Angiotensin-converting enzyme inhibition and food restriction restore delayed preconditioning in diabetic mice.

Authors:  Gerry Van der Mieren; Ines Nevelsteen; Annelies Vanderper; Wouter Oosterlinck; Willem Flameng; Paul Herijgers
Journal:  Cardiovasc Diabetol       Date:  2013-02-23       Impact factor: 9.951

9.  The COX-2/PGI2 receptor axis plays an obligatory role in mediating the cardioprotection conferred by the late phase of ischemic preconditioning.

Authors:  Yiru Guo; Deepali Nivas Tukaye; Wen-Jian Wu; Xiaoping Zhu; Michael Book; Wei Tan; Steven P Jones; Gregg Rokosh; Shuh Narumiya; Qianhong Li; Roberto Bolli
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

10.  Cardiomyocyte-restricted overexpression of extracellular superoxide dismutase increases nitric oxide bioavailability and reduces infarct size after ischemia/reperfusion.

Authors:  Detlef Obal; Shujing Dai; Rachel Keith; Neviana Dimova; Justin Kingery; Yu-Ting Zheng; Jay Zweier; Murugesan Velayutham; Sumanth D Prabhu; Qianghong Li; Daniel Conklin; Dan Yang; Aruni Bhatnagar; Roberto Bolli; Gregg Rokosh
Journal:  Basic Res Cardiol       Date:  2012-10-26       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.